Depakine® (sodium valproate)

Depakine® is a broad-spectrum anti-convulsant. Prescribed for more than 38 years, it remains a first-treatment choice for epilepsy worldwide.

Sodium valproate is available in a large variety of formulations (syrups, soluble drinks, injections, gastro-resistant tablets and Chrono®, an extended-release tablet) in order to cover the full range of patient needs.
Depakine® Chronosphere®, a new sustained-release sachet formulation, has been approved in several European countries. It was launched in Austria in October 2004 and in France and Germany in 2005. This new formulation is easier to use for children (it was the first extended release pediatric form of Depakine®) and for the elderly or adults who have difficulty swallowing. Product launches are planned in most European countries.

Sanofi-aventis has also demonstrated the role this medicine can play in bipolar disorders* which affect approximately 2% of the world’s population and are characterized by alternate manic and depressive episodes. In 2005, Depakine® Chrono® and Chronosphere® were approved for this indication in several European countries.

Sodium valproate is marketed in over 100 countries.

(* The indication in bipolar disorders exist in most of countries).